GMMCDD2024

Dr. Hossein Hosseinkhani, Biomedical Engineer, has 30 years of experience in biomedical engineering in both academia and industry in biomedical engineering research and development, which includes several years of basic science research experience in a number of premier institutions related to the structure and function of biomaterials, and in polymer-based medical implants development in the medical device industry. He is inventor of 22 International patents, several of which are licensed to companies acting in the biomedical fields and translated to 7 commercial products. He authored more than 100 scientific papers published on peer-reviewed Journals, 5 books (H-index: 48 Google Scholar). He is the founder of Matrix HT, Inc. a world leading biotech company dedicated to healthcare technology to improve patient's quality of life.

Dr Kenneth R. Pelletier – is a Clinical Professor of Medicine, Family and Community Medicine, and Psychiatry in the Departments of Medicine and in Psychiatry at the University of California School of Medicine, San Francisco (UCSF) where he is Director of the Corporate Health Improvement Program (CHIP). Dr. Pelletier is also Chairman of the American Health Association, is a Vice President with American Specialty Health (ASH), and is on the Board of Directors of the Rancho la Puerta Resort/Spa. Prior to these positions, Dr. Pelletier served as Clinical Professor, of Medicine, Family Medicine, and as Professor of Public Health at the University of Arizona School of Medicine. Also he served as Clinical Professor of Medicine at Stanford University School of Medicine; was Director of the Stanford Corporate Health Program (SCHP); and was Director of the NIH funded Complementary and Alternative Medicine Program at Stanford (CAMPS). From 1974 until joining the Stanford University School of Medicine in 1990, Dr. Pelletier held a dual appointment as an Associate Clinical Professor in the Department of Medicine and the Department of Psychiatry, University of California School of Medicine in San Francisco (UCSF).

Dr. Lam is a medicinal chemistry and drug discovery consultant. He currently collaborates with Blumberg scientists in terms of drug discovery and jointly supervises Blumberg chemistry postdocs and visiting scientists. Dr. Lam has 30 years of extensive experience in innovation in structure-based drug design, ADME, focused libraries, molecular recognition and nucleic acid therapeutics to deliver biopharma clinical candidates with novel profiles. He is responsible for the discovery of a total of eight clinical candidates. At Bristol Myers Squibb, Dr. Lam was the group leader/co-inventor responsible for the discovery of Eliquis®/Apixaban, a novel Factor Xa anticoagulant recently launched on the market. Eliquis® is projected by analysts to be a transformational medicine with “block-buster” sales potential. Eliquis® was chosen as the “Best New Medicine of 2012” by Med Ad News. He and his team were awarded 2015 American Chemical Society Heroes of Chemistry Award for the discovery of Eliquis®. Dr. Lam is also the inventor of the novel cyclic urea class of HIV protease inhibitors that resulted in Mozenavir/DMP450. In Phase II clinical trial, Mozenavir was shown to be as efficacious as Merck’s Crixivan, but without the lipodystrophy side effect of Crixivan. In recent years, he has been involved with antivirals (HBV capsid, surface antigen and cccDNA inhibitors, Dengue Fever inhibitors, HIV-DCSIGN blockers), antithrombotics (FXIa and FXa inhibitors as anticoagulants; P2Y1 and PAR4 antagonists as antiplatelet agents), PCSK9 antisense oligonucleotide (ASO) therapeutics, prodrugs and carbohydrates. In the organic chemistry area, he is internationally known as the co-discoverer of the powerful copper-promoted Chan-Lam Coupling Reaction, a complementary reaction to the Nobel-prize winning Suzuki-Miyaura Coupling Reaction. Dr. Lam has authored 98 papers/reviews/book chapters, invented 36 patents/patent applications and presented 110 invited seminars worldwide.

Vladimir Torchilin got his M.S, Ph.D., and D.Sc. degrees from the Moscow State University and currently serves as a University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. He has published more than 450 original papers, more than 200 reviews and book chapters, wrote and edited 15 books, and holds more than 40 patents. Google Scholar shows more than 80,000 citations of his papers with H-index of 127. He is Editor-in-Chief of Current Drug Discovery Technologies and Drug Delivery, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $20 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010. In 2021 Elsevier/Stanford analysis ranked him as a single highest-cited researcher among more than 130,000 ranked researches in the area of Pharmacology/Pharmacy.

Will Be Updated Soon

Will be updated soon

Biography: Dr. Steven Deak is a vascular and general surgeon who practices at the Deak Vein NJ Clinic with an emphasis on the treatment of venous diseases. He has been in private practice for over 35 years specializing in vascular and general surgery. Dr. Deak has a Ph.D. degree in Pharmacology from the University of Kentucky. He is a member of the American Venous Forum and the American College of Phlebology. He is interested in the biology of the lymphatic and venous circulation and new techniques for the treatment of varicose veins. He graduated from Georgetown University with a B.S. (Biology) and M.S. (Physiology). He received his M.D. and Ph.D. (Pharmacology) degrees from the University of Kentucky. He received his surgical and vascular training at the Johns Hopkins Hospital and Rutgers-Robert Wood Johnson University Medical School. Dr. Deak is certified by the American Board of Surgery in the specialty of General Surgery. He is certified by the American Board of Phlebology. He is also certified as having Added Qualifications in General Vascular Surgery. He is a fellow of the American College of Surgeons. He is a member of the Society of Vascular Surgery, the American Venous Forum, the American College of Phlebology, the Hungarian Medical Association of American and the International Society for Vascular Surgery.

Maria Carmina Scala is assistant professor at the Department of Pharmacy of the University of Salerno. In 2017, she obtained Ph.D. in Drug Discovery and Development. Her research is focused on peptide and peptidomimetic synthesis trough application of sustainable and innovative synthetic methods by microwave and combinatorial synthesis to achieve small libraries of biologically active compounds. Research projects focus on the study of peptides as antitumor and antiviral agents, peptides active towards the cardiovascular system and for the ocular drug delivery. She has excellent knowledge of biophysical techniques to evaluate the interactions between biological macromolecules, as SPR, MST and DSF, and biochemical techniques, as TR-FRET, LANCE, HTRF. She is also collaborating with various research centers. She has a numerous publication and has participated in different national and international conferences.

Alfonso Zambon is an organic/medicinal chemist with experience in all phases of drug discovery, from hit identification to preclinical development. He obtained his PhD in Organic Chemistry at the Cà Foscari University of Venice and spent post-doctoral periods in Lyon and Geneve; he then joined the Insitute of Cancer Research (ICR)in London, where he contributed to several drug discovery programmes over 10 years. He is currently Associate Professor in Organic Chemistry at the Univesity of Modena and Reggio Emila, Italy. His main research focus has been on the development of targeted anti-cancer agents by multiparametric PK/PD optimisation of inhibitors of intracellular and extracellular targets. He is co-author of over 60 peer-reviewed publications and 40 patents in national phase. Current research interests include the development of bioactive hybrid organic-inorganic materials with modulable physical-chemical properties and the structure based design synthesis of multi-targeted kinase inhibitors and chemical probes.

Federica Moraca currently is Assistant Professor at the Department of Pharmacy in the University of Naples “Federico II” in the Biological Simulation and Drug Desing laboratory (BioSimDDLab). In 2014 she got her Ph.D. in Pharmaceutical Science at the “Magna Graecia” University of Catanzaro. Her research activity is mainly focused in all-atoms Molecular Dynamics (MD) simulations and in enhanced sampling methods (e.g Metadynamics) aimed at describing long time-scale events in systems of biological relevance (e.g. peptides folding, ligand/protein or ligand/DNA molecular recognition etc.), with particular focus in the binding/unbinding process between a ligand and its biological target. Her expertise involves also ligand and structure -based pharmacophore model generation and virtual screening techniques applied for drug-discovery or drug-repurposing processes. Currently, she is co-author of 47 original papers in the field of medicinal chemistry.

Prof. Irena Kostova is one of the World’s Top 1% of scientists according to Stanford University's ranking of scientists with the greatest contribution to the development of modern science. She graduated from Mendeleev University in Moscow with the highest grade. Defended her PhD and DSc theses at MU-Sofia where she is currently a full professor at Chemistry Department. Graduated her second specialization “Theoretical bases of medical chemistry” at MU-Sofia. Her research interests include the developmental work in theoretical and coordination chemistry, vibrational spectroscopy, pharmacological investigations of biologically active compounds etc. Author of about 200 publications with high impact factor and h-index, several textbooks, education book materials and monographs with around 7000 citations in indexed journals. She has been a lecturer at renowned universities in India, Austria, Italy, Romania, Spain, Slovakia etc. Member of the organizing committees of over 30 international conferences. She is an Editor of 7 prestigious international scientific journals, a member of the Editorial Boards of over 25 international journals and a reviewer for numerous high-ranking journals and international projects. She has created and maintains collaborations with a number of European universities in the framework of joint research projects and European programs.

David A Dawson is an endocannabinoid specialist, medical cannabis researcher, and educator. He currently acts in the position of Chief Science Officer for Aeon Bio Health and is involved in research, caring for patients, and preparing to defend his Ph.D. dissertation. He is also the author of multiple peer-reviewed publications in scientific journals, the textbook Medical Cannabis: The Definitive Guide and the novel Pummeled to Death by Hamburger.

In 1991 he obtained his Laurea in chemistry, at the University of Milan, Italy, working on the stereoselective 1,3 dipolar cycloadditions of nitrones to chiral allyl ethers. In 1994 he completed his doctoral studies on the stereoselective synthesis of β-lactams through condensation of imines to titanium, tin and β-boron enolates of pyridylthioesters, under the supervision of prof. Mauro Cinquini, at the University of Milan. In 1995, he was the recipient of a N.A.T.O./CNR postdoctoral fellowship and joined the group of prof. Jay. S. Siegel, at the Chemistry and Biochemistry Department of UCSD, University of California, San Diego where he worked for two years on the stereocontrolled synthesis of supramolecular structures, like double helicates, racks, and grids, useful intermediates for the construction of not trivial topological structures. In 1997 he moved back to Milan, where he worked as postdoctoral fellow at the Department of Organic and Industrial Chemistry, University of Milan, developing the stereoselective synthesis of polymer supported small organic molecules. In 2000 he became assistant professor at Department of Organic and Industrial Chemistry, University of Milan and in 2006 associate professor at the University of Milan. In 2006 he was promoted to Associate Professor at the University of Milano. After obtaining the habilitation in 2013, he was promoted in 2015 to Full Professor in Organic Chemistry at the Department of Chemistry, University of Milano, Italy.

Will Be Updated Soon

will be updated soon

Dr. Jufan Zhang received his PhD degree in 2009 from Harbin Institute of Technology, China. After working in the industry for years, he returned to the academia as the postdoctoral fellow, and then hosted several major funding as the PI. He joined the Centre of Micro/Nano Manufacturing Technology, University College Dublin (UCD), Ireland in 2017, and now is working as the lecturer/assistant professor in UCD School of Mechanical and Materials Engineering. His research interests mainly include the design and manufacturing of medical devices and bioimplants, micro/Nano functional structures, geometrical waveguide design and manufacturing, etc.

Dr Leandro Castellano obtained his BSc in Biology at the University of Salento, Italy. He then moved to Rome at the University “La Sapienza” where he completed a PhD in Human Biology and Genetics (2003-2007) working during the first year on the role of Post Transcriptional Gene Silencing (PTGS) in the Circadian Rhythm of the filamentous fungus Neurospora Crassa and later, on the role of microRNAs in human Cell Cycle and in Chronic Lymphocytic Leukaemia (CLL). He moved to Imperial College London in 2007 where he worked as a Research Associate focusing on the role of microRNAs in epithelial cancers. From 2011 he was appointed as Team Leader at the Division of Surgery and cancer, at Imperial, where he directly supervised several PhD students, Research Associates and Research Assistants. During these years Dr Castellano research interests expanded from microRNAs to the role of various classes of short and long non-coding RNAs in epithelial cancer development and progression. He is the Head of Department of Biochemistry and Biomedicine and a Reader (Associate Professor) in RNA Biology at the University of Sussex and holds an honorary position at Imperial College London as visiting Reader. He is also the Designated Individual (DI) under the Human Tissue Act at the School of Life Sciences at the University of Sussex. He is a fellow of the higher education academy (FHEA).

Rajendran (Raj) Arunagiri is the Global Pharma Segment Manager at Eastman. He has nearly a decade of experience in the pharma industry interfacing with the entire pharma value chain across the globe. His expertise is understanding global drug delivery trends. Raj has an Electrical Engineering degree from India and an MBA from USA.

Prof. Liangfang Zhang received his Ph.D. in Chemical Engineering from the University of Illinois at Urbana- Champaign (UIUC) in 2006 under the supervision of Prof. Steve Granick. He was a postdoc in the laboratory of Prof. Robert Langer at MIT during 2006-2008. He holds B.E. and M.S. degrees in Chemical Engineering from Tsinghua University. He joined the Department of Nanoengineering at UC San Diego as Assistant Professor in 2008 and was promoted to Associate Professor with tenure in 2012 and to Professor in 2014.

Sherif Fahmy received his BSc and MSc degrees from Cairo University, and his PhD degree in Mechanical and industrial engineering from the University of Manitoba, Winnipeg in 2009. He has more than 17 years of academic experience, from teaching assistant to associate professor, in Egypt, Canada, and Kuwait. Fahmy also worked as a process manager in the area of healthcare improvement using lean and six sigma and various industrial engineering techniques. He also has extensive experience in innovation management, IP management, and technology transfer and commercialization, as he had been managing the innovation program in Egypt’s biggest fund for science and technology. He has been a member of many professional societies, a reviewer for a number of academic journals, and he is also a registered professional engineer (PENG) in Canada and in Egypt.

Ivan V Maksimovich, MD, PhD. ISTAART member, ESC member, EAPCI member, WSO member, ESO member, EPA member. Head Physician of Clinic of Cardiovascular Diseases named after Most Holy John Tobolsky (Moscow, Russia) since 1993. One of the major problems the clinic deals with is the diagnosis and treatment of various brain lesions including Alzheimer's disease. Over the past 20 years I have published over 200 scientific works on this subject.

I am Assistant Professor in Pharmaceutical Chemistry working at Dr. L. H. Hiranandani College of Pharmacy, Ulhasnagar (Affiliated to the University of Mumbai). I am a recognized Guide and Chairperson, Paper Setter, and Examiner for Ph.D. (Pharmaceutical Chemistry), M. Pharm. (Pharmaceutical Chemistry), and M. Pharm. (Quality Assurance) at the University of Mumbai. Guided 16 M. Pharmacy students. Member of Pharmacy Council of India, Association Pharmaceutical Teachers of India, and KPSF. I have Completed 4 Research Projects funded by the University of Mumbai. Worked at Cipla Ltd., Okasa Pharma trainee. Completed projects in the R & D Department of Excel Industries Pvt. Ltd., Supriya Lifesciences Ltd., and Jubilant Pharma and Chemical Lab (OPC) Pvt. Ltd. Acted as an Organizing Committee Member, Panelist, Moderator, and Keynote Speaker and presented invited lectures on Drug Discovery and Design, and CADD at the 5th Annual Congress on Chemistry in Drug Discovery & Designing” held in Dubai, UAE. And at the International Conference on Chemistry and Pharmaceutical Chemistry in the UK. On the Panel for the International Webinar on Chemistry and Pharmaceutical Chemistry, UK. Acted as a Resource person for national conferences on Drug Discovery and Design and development. Molecular Modeling, Stability Studies of Ayurvedic Drugs. Won many awards for the Research Projects. 7 Research Publications, and 21 national and international presentations.

Dr. Tathagata Dutta has earned his M.Pharm and PhD in Pharmaceutical Sciences from Dr. Hari Singh Gour University, Sagar and completed his postdoctoral studies from School of Pharmacy & Diamantina Institute for cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, Australia and was engaged in development of RNAi therapeutics for effective management of cancer. He is an alumni if IIM Calcutta. He has served as Chief Scientific Officer (CSO), Vice President (R&D), Executive Director, and Managing Director & CEO of several reputed Multinational Pharmaceutical Companies across the globe for more than two decades. He has been conferred with several National and International Awards and Honors. He has published several international papers in reputed international journals, several patents and had authored several book chapters. He is the editorial board member of several international journals on drug discovery & delivery research. His research interests include novel drug delivery systems, dendrimers, liposomes, polymer bioconjugates, tissue targeted drug delivery systems, nano drug delivery systems, gene therapy, genetic immunization, depot injections, gene delivery, and development of RNAi therapeutics.

Dr. Srinivasan Jayakumar is a distinguished Postdoctoral Research Associate at Rensselaer Polytechnic Institute in Troy, New York, USA. With over eight years of research experience, including five years in industrial settings at Syngene International Pvt Ltd, India, he specializes in Synthetic Organic and Medicinal Chemistry. Dr. Jayakumar holds a Ph.D. in Organic Chemistry from National Tsing Hua University, Taiwan, and a Master's degree in Chemistry from Guru Nanak College, University of Madras, India. In 2020, Dr. Jayakumar moved to the U.S. to continue his postdoctoral research at Albany College of Pharmacy and Health Sciences, NY, before joining Rensselaer Polytechnic Institute. His research primarily focuses on the development of GlyT2 inhibitors for neuropathic pain management and RBP4 antagonists for treating age-related macular degeneration, Transthyretin Amyloidosis, and their associated age-related comorbidities. In addition to his research endeavors, Dr. Jayakumar is actively engaged in the scientific community through his roles on the editorial boards of multiple international chemistry journals and as a peer reviewer for various organic chemistry journals. His publications span a range of topics in medicinal and synthetic organic chemistry, highlighting his broad expertise and dedication to furthering the field.

Mariana Spetea earned a M.Sc. degree in Biochemistry from the University of Bucharest, Romania, and her Ph.D. degree in Biology from the József Attila University, Szeged, Hungary. She spent two years as a post-doctoral fellow at the Karolinska Institute in Stockholm, Sweden, with research fellowships awarded by the Swedish Institute and the Wenner-Gren Center Foundation. She has joined the ‘Opioid Research Group’ at the University of Innsbruck in Austria, as a research associate and assistant professor, where she has habilitated in Pharmacology. Since 2011, she is the head of the ‘Opioid Research Group’. An important focus of her research is dedicated to opioid drug discovery and development. Central topics of her research include structure-activity relationships of new opioid ligands, modulation of the ligand/opioid receptor system in pathological pain and molecular mechanism of opioid actions. She has been a research leader and associate researcher of several research projects, as well as the scientific coordinator of a European Union research project. Besides science, Prof. Spetea is devoted to education in Pharmaceutical Sciences of undergraduate and graduate students at the Faculty of Chemistry and Pharmacy, University of Innsbruck. Her scientific achievements have been published in numerous peer-reviewed articles, reviews, conference proceedings and patents, and have been disseminated in popular science reports. Beside several numerous awards, she was also the receiver of “Science4Life Venture Cup 2003”. Prof. Spetea is Editorial Board Member of Frontiers (Frontiers in Neuroscience, Pharmacology, Neurology, Psychiatry and Drug Discovery) and Molecules (MDPI).

Professor Phila RAHARIVELOMANANA, Natural product Chemist (Ph.D.-Chemistry), Now is a Full professor of Chemistry at the University of French Polynesia. She obtained her PhD diploma in Molecular Chemistry at the University of Nice Sophia-Antipolis (France) in 1992. She has more than 20 years of experience in phytochemical science research in academia. Since 1993, she got a faculty position at the University of French Polynesia (respectively Assistant Professor in 1992, Associate Professor in 1993 and Full Professor in 2004) as a chemistry teacher and phytochemical researcher working on Pacific and Polynesian plants. When she joined the UPF in the early 1990s, she was one of the pioneer researchers working in phytochemistry of Polynesian plants. Then, she focused to medicinal plant investigation aiming at a better understanding of ethnopharmacological aspects and evaluation of their biological activities beyond their chemical composition assessment, including studies of a wide variety of bioactive secondary metabolites.

Professor Dr. Mohammad Kamil is a recipient of many prestigious honours & awards viz Young Scientist’s Award, India(1998); Common Wealth Award-London(1992); Convention Award of Chemical Society-India(1993); HakimAjmal Khan Shield (CCRUM-Govt. of India at Grant Medical College (1992);Academic Exchange Fellowship from Association of Common Wealth Universities –London(1993); Acted as an Expert on the panel of Union Public Service Commission (UPSC),India,2000. ;Man of the year 2002, ABI, USA ;Hakim Ajmal Khan Global Award in Unani Medicine, India(2014); Focal Point of WHO Collaborative Sheikh Zayed Research Centre Abu Dhabi for 8 years; Sheikh Zayed International Award in Herbal Research (2020) and various other prestigious honors & awards. Dr. Kamil produced 20 Ph. D. and M.Phil. students besides a large number of M. Sc. and Interns. More than 450 research papers in reputed journals & presentations at international conferences are at his credit, chaired a no. of scientific sessions , delivered talks as plenary and invited speaker at various International Conferences. Associated with publication of many books; authored six books and five chapters in different books.

I am a scientist, technologist, and entrepreneur with over 15 years of experience in artificial intelligence, health, data science, and cryptocurrencies. I am currently the Chief Innovation Officer at Sama Therapeutics, where I lead the development of the iMAGiNE precision neuropsychiatry AI/ML platform. This platform enables transdiagnostic biomarker discovery for drug and device development, fundamental neuroscience research, and patient clinical decision support. I have co-founded and served as the Chief Scientific Officer of several companies in the AI and biotech domains, with successful exits and acquisitions. I have also conducted scientific and technical due diligence on $100M+ transactions in AI drug discovery. I have published scientific papers in peer-reviewed journals on AI and neurodegenerative disease, neuropathology, immunology, biosensors, and radiology. As a keynote speaker and conference moderator, I have spoken at conferences worldwide on biotechnology, AI, cryptocurrencies, and neurotechnology for diverse audiences. My mission is to leverage AI, synthetic biology, and data science to advance human health and wellbeing around the world.

Bastiaan Bergman, PhD - VP of Engineering, Model Medicines Physicist by education; moved to Silicon Valley for my first job. At IBM (2005-2009) I did fundamental research at a novel computer memory, and built a pulsed laser tool for measurement of magnetic domain wall activity in nanowires. The work was published in PRL, Nature and other journals. The memory came to market as ST-MRAM in 2016. Then, at WD (2009-2018), worked in nano-physics and material science. Here, at the magnetic heads production site we made 3 million heads per day and my team was responsible for the measurements of a range of physical properties on these heads in the production line. When data grew, I started using AI to make better use of the data and predict yield and performance metrics online in the production line. In 2017 I competed in the Passenger Screening Algorithm Challenge, an AI competition with the US Department of Homeland Security (DHS) for predicting contraband on airline passengers as they move through the microwave scanners at airports. In that competition I won second place, and then decided to do something else with this new AI skill. In 2018 I joined Atomwise, with the early team of about 10 scientists. With Atomwise we basically pioneered the idea of using AI for drug discovery. The company grew fast and I was heavily involved in every AI project that Atomwise worked on in those years. Through my experience with AI, experimental data in general, and having learnt more about the intricacies of pharmacology I decided in 2021 that it was time for a new approach for AI in pharmacology. In 2021 I joined Model Medicines, joining a team with a strong focus on bringing a drug to the patient.

Dr. Lee is a dedicated researcher with a focus on studying the role of the circadian clock in disease and treatment. He obtained their B.A, M.S, and Ph.D. from Seoul National University in South Korea, where their research centered around the molecular mechanisms of the circadian clock. Following this, Dr. Lee pursued postdoctoral research at the University of Pennsylvania, where they developed innovative methods to investigate the involvement of the circadian clock in various diseases, particularly cancer. During their postdoctoral work, Dr. Lee made significant discoveries by identifying novel clock-regulating molecules using a combination of in vitro, in vivo, and bioinformatics approaches. Dr. Lee also explored the impact of circadian disruption on cellular and metabolic physiology in cancer and neurodegenerative diseases. Additionally, Dr. Lee developed chrono-pharmacological screening techniques to gain

Diana V. Aleksanyan studied chemistry at the Higher Chemical College of the Russian Academy of Sciences and received her PhD degree in 2011 from the Nesmeyanov Institute of Organoelement Compounds (INEOS RAS). Currently she is a senior researcher in the Laboratory of Organophosphorus Compounds at the INEOS RAS. Her main research interests include organophosphorus and organometallic chemistry, solvent-free reactions, and mechanochemistry, and design of biologically active transition metal complexes.

Dr. R. Velmurugan has completed his M.Sc (Chemistry) in 2007 and Ph.D (Synthetic Organic Medicinal Chemistry) in 2012 from Bharathiar University, Coimbatore, Tamil Nadu, India. In 2011 he joined as an Assistant Professor in the Department of Chemistry, Kongunadu Arts and Science College, Coimbatore, Tamil Nadu, India. Currently, in his research group 3 Ph.D and 1 M.Phil students are working on various synthetic Organic Chemistry field. He has produced 2 Ph.D Candidate in the field of Organic Medicinal Chemistry. Dr. R. Velmurugan has been published about 35 Scientific papers in high reputed international journals which have been received more citations. He has reviewed several Manuscripts for more than 5 international journals from various publishers, like, Elsevier, Bentham Chemistry, etc… Dr. R. Velmurugan is a member of Indian Science Congress Association, Kolkata. He is a Member in Board of Studies at Various Educational Institutions.